Business
Patent application
Patent application.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n \n \n \n REACH\n \n \n \n \n \n \n 21 March 2023\n \n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n \n (\"Fusion\" or the \"Company\")\n \n \n \n \n \n \n Patent application\n \n \n \n \n \n \n \n \n Fusion Antibodies plc (AIM: FAB), a contract research organisation (\"CRO\") providing discovery, design, and optimisation services for therapeutic antibodies to the global healthcare market,\n announces that it has filed a patent application for a panel of antibodies that bind to an important target for cancer therapeutics. These antibodies have the potential to inhibit the pro-tumourigenic activity of their target in cancer, which is supported by pre-clinical data. The Company is exploring options to out-licence these antibodies to a clinical development company to progress them into Phase I clinical trials.\n \n \n \n \n \n \n Dr Adrian Kinkaid, CEO of Fusion, commented\n \n \n : \"We have a dedicated team of scientists who continue to work on antibody discovery and expression, and we remain confident in our ability to grow and create opportunities in this field. We look forward to being able to update the market further, whilst also growing our patent portfolio.\"\n \n \n \n \n \n \n \n \n \n Enquiries: \n \n \n \n \n \n \n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n \n \n \n www.fusionantibodies.com\n \n \n \n \n \n \n Adrian Kinkaid, Chief Executive Officer\n \n \n James Fair, Chief Financial Officer\n \n \n \n \n \n Via Walbrook PR\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Allenby Capital Limited\n \n \n \n \n \n Tel: +44 (0)20 3328 5656 \n \n \n \n \n \n \n James Reeve / Vivek Bhardwaj (Corporate Finance)\n \n \n Tony Quirke (Sales and Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR\n \n \n \n \n \n Tel: +44 (0)20 7933 8780 or [email protected]\n \n \n \n \n \n \n Anna Dunphy\n \n \n \n \n Mob: +44 (0)7876 741 001\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n About Fusion Antibodies plc\n \n \n \n \n \n \n Fusion is a Belfast based contract research organisation (\"CRO\") providing a range of antibody engineering services for the discovery and development of antibodie...